Business
Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics
Collaboration Will Continue to Work Towards Identifying Biomarkers for Protective Immunity Against SARS-CoV-2 Immune Correlates of Protection May Support
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"Collaboration Will Continue to Work Towards Identifying Biomarkers for Protective Immunity Against SARS-CoV-2 Immune Correlates of Protection May Support Development of New and Specialized Vaccines to Protect Against COVID-19 Potential for Developing Antibody-Based COVID-19 Therapeutics as a Result of the Collaboration CHATHAM, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has expanded its research collaboration with Columbia University. The research collaboration is focused on studying immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic, as well as studying in vitro T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation for tailoring vaccines and therapeutics to appropriate individuals with precision medicine. The two principal investigators for the collaboration are Ilya Trakht, Ph.D., Associate Research Scientist and Sergei Rudchenko, Ph.D., Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons. Dr. Trakht is studying T cell and antibody responses in a variety of ways, including at the cellular level by stimulating T cells in vitro with CoV-2 antigens and by generating fully human monoclonal antibodies against SARS-CoV-2. This research has the potential to lead to the isolation, characterization and cloning of therapeutically relevant fully human neutralizing monoclonal antibodies to SARS-CoV-2. Dr. Rudchenko is generating DNA aptamer-based anti-idiotypes to certain monoclonal antibodies identified by Dr. Trakht. Such aptamers have the potential to identify biomarkers for protective CoV-2 immunity and accelerate the design of precision medicine-driven vaccines against COVID-19. “Based on the progress and results of the initial phase of these projects, we are excited to expand our research collaboration with Columbia University on these precision medicine technologies and also to potentially develop new monoclonal antibody therapeutics,” stated Seth Lederman, M.D., President and Chief Executive Officer of Tonix. “Data from this collabo...